Retail Today | Global News: Muji Is Struggling from Overseas Markets 今日零售 | 全球視點: 無印良品 海外市場的巨大挑戰 (中文在下)
In April, Muji's parent company Ryohin Keikaku Co. reported its first decline in operating profit in eight years and a financial outlook below analysts’ expectations, as well as a rare drop in same-store sales in China.
Investors are worried: After the value of the company almost tripled from 2013 to 2018, Ryohin Keikaku shares have declined nearly 40% in the past year.
President Satoru Matsuzaki has embarked on new ventures like Muji-branded hotels and Muji-designed buses while pushing into new markets such as India and Switzerland. To drive growth, he’s now taking steps like shifting production to cheaper locations and designing products specifically for Chinese consumers.
However, Muji still requires a faster adjustment to its overseas sales strategies. Muji always expanded to other countries with the same items it sells in Japan, assuming that its product range needs little translation for overseas consumers. That works well enough for, say, pencil cases, but not necessarily other items: It took Muji a decade in China to introduce sheets that fit standard Chinese beds.
Meanwhile, Muji’s “no brand” branding and straightforward, unchanging designs have made it a prime target for low-cost Chinese copycats. Muji’s prices are considerably more expensive outside of Japan due to taxes and tariffs, and a cottage industry of Chinese competitors like Miniso, Nome and OCE has sprung up to offer the same aesthetic for a fraction of the cost.
To avoid the price competition, Muji plans to produce more of its items in the countries where they’re sold. Next year, the company will roll out over 200 made-in-India products for its local stores. It’s also shifting more production to Southeast Asia, where labor is cheap.
In China, it opened its first development office in September, with employees responsible for monitoring local lifestyle trends—a belated acknowledgment that Tokyo-based designers may not have the necessary insight into Chinese desires. Not everything will be internationalized, however. Muji will continue to make cosmetics, for example, in Japan, as the promise of high-quality raw materials is part of their allure.
Given how quickly its low-cost imitators have moved, Muji faces an uphill battle in China. And there and elsewhere, its ambition to become a global retail behemoth to match Uniqlo may require some of the strategic compromises made by other mass retailers—whittling its 7,000 products down to those of greatest sales potential, manufacturing items for speed rather than durability, and opening large locations in expensive shopping districts.
今年四月,無印良品的母公司 Ryohin Keikaku Co. 報告中顯示,8年來他們的營業利潤首次下滑、財務前景低於分析師的預期,以及中國同店銷售額出現罕見的衰退。
投資者擔心,在2013年至2018年間,公司價值幾乎翻了三倍之後,Ryohin Keikaku 股價卻在過去一年中,下跌了將近40%。
品牌董事長 Satoru Matsuzaki 已開展新的企業體,包括開設無印良品酒店、無印良品設計的巴士,同一時間也進軍印度和瑞士等新市場。為了推動增長,他正在採取新措施,例如將生產工廠轉移到成本更便宜的地方,並專門為了中國消費者設計產品。
然而,無印良品仍需要更快速調整海外銷售策略。Muji 在拓展到其他國家時,多半採取與日本銷售產品相同的策略,也就是假定自家產品到其他市場販售,並不需要太多的修改或客製化。這對鉛筆盒這類商品是還不錯,但卻不一定可以複製到其他品項;舉例來說,無印良品實際上花了十年,才推出適合中國標準床尺寸的床單。
同時,無印良品的「無品牌」品牌、直觀和一成不變的設計,使它變成中國低成本仿冒商的主要目標。由於稅收和關稅的影響,無印良品在日本以外的價格相當昂貴,而Miniso,Nome和OCE等中國競爭對手,透過大量的家庭手工業製造,只需花費很少的成品,就能為消費者提供相同的生活美學。
為了避免落入價格競爭,無印良品計劃在其銷售的國家生產更多產品。明年,他們將為印度門市推出200多種當地製造的產品。還計畫將更多產品轉移到勞動力便宜的東南亞。
在中國,無印良品在去年九月成立第一個開發辦公室,員工負責觀察、搜集當地的生活方式趨勢 - 這也代表著無印良品終於承認,在東京的設計師不見得了解中國當地消費者真正的需求。然而,並非需要把一切都做到國際化。例如,無印良品選擇繼續在日本生產化妝品,因為日本所代表的高品質原材料是一項承諾,仍對消費者存在著重大的吸引力。
因為低成本仿造商的快速推進,無印良品在中國正面臨著一場苦戰。他們將自己定位與全球零售巨頭「優衣庫」齊頭並進的野心,可能需要參考其他大眾零售商一些在戰略上的妥協 - 像是把七千種產品減少,直到只保留最具銷售潛力的品項、快速製造商品而非強調產品的耐久度,以及在高消費購物區開設大型旗艦店等。
同時也有10000部Youtube影片,追蹤數超過2,910的網紅コバにゃんチャンネル,也在其Youtube影片中提到,...
「make adjustment中文」的推薦目錄:
- 關於make adjustment中文 在 SkyREC Facebook 的最讚貼文
- 關於make adjustment中文 在 眼科陳慶隆醫師-視網膜的大小事 Facebook 的最佳解答
- 關於make adjustment中文 在 コバにゃんチャンネル Youtube 的最佳解答
- 關於make adjustment中文 在 大象中醫 Youtube 的最讚貼文
- 關於make adjustment中文 在 大象中醫 Youtube 的精選貼文
- 關於make adjustment中文 在 翻譯這檔事- 「校正回歸」說是retroactively... | Facebook 的評價
- 關於make adjustment中文 在 Adjusting Entries - YouTube 的評價
make adjustment中文 在 眼科陳慶隆醫師-視網膜的大小事 Facebook 的最佳解答
術後可調整度數及散光的人工水晶體 RxSight,正式被美國FDA通過,如果未來能在台灣上市,將是眼科醫師與患者的一大福音!
美國食品藥物管理局(FDA)昨(22)日批准了RxSight的光調節水晶體(light adjustable lens)和光傳遞設備(light delivery device, LDD),這是第一個可以在白內障手術後,對人工水晶體(intraocular lens, IOL)進行小幅度調整的醫療器械系統,幫助患者不戴眼鏡也能擁有良好視力。
白內障通常是由於年紀增長,水晶體變硬或混濁,影響患者視力。也有些是由於外傷性、併發性(如青光眼)、代謝性(如糖尿病)等引起的白內障。
解決療法之一便是進行人工水晶體置換手術,然而許多患者會有些微屈光不正,需要使用眼鏡或隱形眼鏡矯正。
為了替患者解決人工水晶體不當聚焦的問題,RxSight 建構獨特材料IOL,在手術後17至21天,對LDD發出的紫外線進行反應。根據所需調整量,患者在1到2周內接受3或4次光照治療,每次約40-150秒。
白內障手術開始到光療結束,患者必須配戴特殊眼鏡防護紫外線,保護新水晶體免受紫外線照射影響。
FDA批准是基於針對此產品所做的試驗成果,該研究隨機性地在17個研究地點挑選600名患有散光的患者,比較了光調節水晶體與現有的單焦點水晶體。
使用光調節水晶體的患者接受輕度LDD治療,術後6個月的裸眼視力(uncorrected visual acuity, UCVA)達到20/20或更高,是接受單焦點水晶體患者的兩倍。與使用傳統IOL相比,患者平均遠距離裸眼視力在視力表上可多看清楚一行。
75%的患者散光也有所減少,91.8%使用光調節水晶體的患者也達到目標驗光球鏡度數(manifest refraction spherical equivalent)0.5D以內的結果,這與近期LASIK研究中所見屈光準確性相似。
FDA醫療器械暨輻射健康中心(Center for Devices and Radiological Health)眼科和耳鼻喉科部門主任Malvina Eydelman表示,到今天為止,白內障手術常見的屈光不正問題,都還得透過眼鏡矯正。不過這個系統為部分患者提供了一個新的選擇,使醫生在初次手術後,可進行多次,可在辦公室內操作的步驟,對植入的水晶體做些調整,提高不戴眼鏡的視力。
RxSight執行長Eric Weinberg指出,我們很高興全球首個手術後可調式IOL成功到達另一個里程碑,這對期待屈光人工水晶體技術再度突破的患者、外科醫生和驗光師來說,是一個相當令人振奮的機會。我們很感謝所有參與這項工作的人員,包括協助研究的臨床工作人員,以及準備審查監管報告的雙方(RxSight和FDA)工作人員。
感謝 David 提供中文翻譯。
資料來源:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586405.htm
The U.S. Food and Drug Administration today approved the RxSight Inc. Light Adjustable Lens and Light Delivery Device, the first medical device system that can make small adjustments to the artificial lens’ power after cataract surgery so that the patient will have better vision when not using glasses.
Cataracts are a common eye condition where the natural lens becomes clouded, impairing a patient’s vision. Following cataract surgery, during which the natural lens of the eye that has become cloudy is removed and replaced with an artificial lens (intraocular lens, or IOL), many patients have some minor residual refractive error requiring use of glasses or contact lenses. Refractive error, which is caused when the artificial lens does not focus properly, causes blurred vision.
“Until now, refractive errors that are common following cataract surgery could only be corrected with glasses, contact lenses or refractive surgery,” said Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat at the FDA’s Center for Devices and Radiological Health. “This system provides a new option for certain patients that allows the physician to make small adjustments to the implanted lens during several in-office procedures after the initial surgery to improve visual acuity without glasses.”
The RxSight IOL is made of a unique material that reacts to UV light, which is delivered by the Light Delivery Device, 17-21 days after surgery. Patients receive three or four light treatments over a period of 1-2 weeks, each lasting about 40-150 seconds, depending upon the amount of adjustment needed. The patient must wear special eyeglasses for UV protection from the time of the cataract surgery to the end of the light treatments to protect the new lens from UV light in the environment.
A clinical study of 600 patients was conducted to evaluate the safety and effectiveness of the RxSight Light Adjustable Lens and Light Delivery Device. Six months after the procedure, patients on average saw an improvement of about one additional line down the vision chart, for distance vision without glasses, compared to a conventional IOL. Six months after surgery, 75 percent also had a reduction in astigmatism.
The device is intended for patients who have astigmatism (in the cornea) before surgery and who do not have macular diseases.
The device should not be used in patients taking systemic medication that may increase sensitivity to UV light such as tetracycline, doxycycline, psoralens, amiodarone, phenothiazines, chloroquine, hydrochlorothiazide, hypercin, ketoprofen, piroxicam, lomefloxacin and methoxsalen. Treatment in patients taking such medications may lead to irreversible eye damage. The device is also contraindicated in cases where patients have a history of ocular herpes simplex virus.
The FDA approved the Vision Light Adjustable Lens and the Light Delivery Device to RxSight Inc.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
make adjustment中文 在 翻譯這檔事- 「校正回歸」說是retroactively... | Facebook 的推薦與評價
「校正回歸」說是retroactively adjust,或任何其他組合,保留「回」和「修/調/改」的意思,最好。 說是backfill (回補、補登)也不錯,是簡潔、對等的 ... ... <看更多>